Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2021-02, Vol.26 (2), p.335-344
Main Authors: Takahari, Daisuke, Shinozaki, Eiji, Wakatsuki, Takeru, Ooki, Akira, Ozaka, Masato, Suzuki, Takeshi, Nakayama, Izuma, Osumi, Hiroki, Kamiimabeppu, Daisaku, Sato, Taro, Ogura, Mariko, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Cancer
Cancer Care Facilities - organization & administration
Cancer Research
Chemotherapy
Coronaviruses
COVID-19
Gastrointestinal Neoplasms - drug therapy
Humans
Infection Control
Japan
Medical Oncology - organization & administration
Medicine
Medicine & Public Health
Morbidity
Oncologists - psychology
Oncology
Original
Original Article
Pandemics
Patients
Practice Guidelines as Topic
SARS-CoV-2
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoing chemotherapy and for practicing healthcare professionals. Various reports have shown data indicating that cancer patients with COVID-19 have high morbidity and mortality rates. In order to reduce the use of medical resources to avoid the risk of COVID-19 infections in both cancer patients and health care providers, oncologists now have to draw the line for cancer treatments by maintaining their efficacy while avoiding severe adverse events. In this article, we outlined the decisions made regarding the practice of gastrointestinal oncology in our institution during the COVID pandemic.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-020-01806-7